Physician perceptions and preferences in the treatment of acquired immunodeficiency syndrome (AIDS)-related lymphoma
| Autor: | Heather A. Leitch, Kevin Imrie, Tony Antoniou, Rena Buckstein, Matthew C. Cheung, Laura Y. Park-Wyllie, Mona Loutfy |
|---|---|
| Rok vydání: | 2007 |
| Předmět: |
Cart
Canada medicine.medical_specialty CHOP Choice Behavior AIDS-related lymphoma Antibodies Monoclonal Murine-Derived Acquired immunodeficiency syndrome (AIDS) immune system diseases Antiretroviral Therapy Highly Active Physicians hemic and lymphatic diseases Internal medicine Antineoplastic Combined Chemotherapy Protocols Humans Medicine Practice Patterns Physicians' Formulary Cyclophosphamide Lymphoma AIDS-Related business.industry Data Collection Antibodies Monoclonal Disease Management Hematology General Medicine Odds ratio Guideline medicine.disease Surgery Doxorubicin Vincristine Prednisone Rituximab business medicine.drug |
| Zdroj: | Annals of Hematology. 86:631-638 |
| ISSN: | 1432-0584 0939-5555 |
| Popis: | The optimal management of acquired immunodeficiency syndrome-related lymphoma (ARL) in the era of combination antiretroviral therapy (cART) is unclear. We administered a survey to determine physician preferences and perceptions in the management of ARL and to assess the variability in treatment in Canada. Of 196 lymphoma-treating physicians, 117 (63%) responded. The majority of respondents (98%) had a positive attitude towards the treatment of ARL. Most physicians (66%) recommended the concomitant use of cART in the care of their patients with ARL, and a majority (86%) recommended CHOP-like regimens (cyclophosphamide, doxorubicin, vincristine, and prednisone) to form the backbone of chemotherapy. The addition of rituximab was preferred by 43% of physicians, while 39% and 18% would either not use rituximab or were unsure of the agent’s role, respectively. In logistic regression analysis, use of rituximab was predicted only by location of practice (province); physicians from the province of British Colombia were much more likely to administer rituximab than practitioners from Ontario (odds ratio 41.8; 95% confidence interval 7.44–235.1, p < 0.001). In the current cART era, physicians have a positive attitude towards the treatment of ARL. The majority prefer to use cART in combination with CHOP for ARL. The use and perceived benefit of rituximab may be influenced by interprovincial formulary differences and regional variation in guideline recommendations. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink